MIRM
Price
$69.25
Change
-$1.53 (-2.16%)
Updated
Nov 13 closing price
Capitalization
3.56B
117 days until earnings call
Intraday BUY SELL Signals
XERS
Price
$7.26
Change
-$0.33 (-4.35%)
Updated
Nov 13 closing price
Capitalization
1.2B
117 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MIRM vs XERS

Header iconMIRM vs XERS Comparison
Open Charts MIRM vs XERSBanner chart's image
Mirum Pharmaceuticals
Price$69.25
Change-$1.53 (-2.16%)
Volume$2.01M
Capitalization3.56B
Xeris Biopharma Holdings
Price$7.26
Change-$0.33 (-4.35%)
Volume$2.74M
Capitalization1.2B
MIRM vs XERS Comparison Chart in %
MIRM
Daily Signal:
Gain/Loss:
XERS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MIRM vs. XERS commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MIRM is a Hold and XERS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (MIRM: $70.78 vs. XERS: $7.59)
Brand notoriety: MIRM and XERS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MIRM: 72% vs. XERS: 127%
Market capitalization -- MIRM: $3.56B vs. XERS: $1.2B
MIRM [@Biotechnology] is valued at $3.56B. XERS’s [@Biotechnology] market capitalization is $1.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MIRM’s FA Score shows that 1 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • MIRM’s FA Score: 1 green, 4 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, MIRM is a better buy in the long-term than XERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MIRM’s TA Score shows that 4 TA indicator(s) are bullish while XERS’s TA Score has 5 bullish TA indicator(s).

  • MIRM’s TA Score: 4 bullish, 4 bearish.
  • XERS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XERS is a better buy in the short-term than MIRM.

Price Growth

MIRM (@Biotechnology) experienced а +0.98% price change this week, while XERS (@Biotechnology) price change was -23.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

MIRM is expected to report earnings on Mar 11, 2026.

XERS is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MIRM($3.56B) has a higher market cap than XERS($1.21B). XERS YTD gains are higher at: 123.894 vs. MIRM (71.173). XERS has higher annual earnings (EBITDA): 7.39M vs. MIRM (-18.79M). MIRM has more cash in the bank: 305M vs. XERS (59.3M). XERS has less debt than MIRM: XERS (257M) vs MIRM (319M). MIRM has higher revenues than XERS: MIRM (429M) vs XERS (246M).
MIRMXERSMIRM / XERS
Capitalization3.56B1.21B295%
EBITDA-18.79M7.39M-254%
Gain YTD71.173123.89457%
P/E RatioN/AN/A-
Revenue429M246M174%
Total Cash305M59.3M514%
Total Debt319M257M124%
FUNDAMENTALS RATINGS
MIRM vs XERS: Fundamental Ratings
MIRM
XERS
OUTLOOK RATING
1..100
1176
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
872
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
4140
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIRM's Valuation (55) in the null industry is in the same range as XERS (86) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew similarly to XERS’s over the last 12 months.

MIRM's Profit vs Risk Rating (8) in the null industry is somewhat better than the same rating for XERS (72) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew somewhat faster than XERS’s over the last 12 months.

MIRM's SMR Rating (95) in the null industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that MIRM’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as MIRM (41) in the null industry. This means that XERS’s stock grew similarly to MIRM’s over the last 12 months.

XERS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as MIRM (100) in the null industry. This means that XERS’s stock grew similarly to MIRM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MIRMXERS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 18 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
66%
Bearish Trend 7 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
57%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
MIRM
Daily Signal:
Gain/Loss:
XERS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBNCX14.910.07
+0.47%
Neuberger Berman International Sel C
TEDIX32.660.14
+0.43%
Franklin Mutual Global Discovery A
BGIUX15.750.04
+0.23%
Baillie Gifford International Alpha 4
STMGX34.50N/A
N/A
American Beacon Stephens Mid-Cap Gr Inv
RGSCX22.38-0.08
-0.36%
Virtus KAR Global Small-Cap C

MIRM and

Correlation & Price change

A.I.dvisor indicates that over the last year, MIRM has been loosely correlated with XERS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MIRM jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIRM
1D Price
Change %
MIRM100%
-0.76%
XERS - MIRM
51%
Loosely correlated
+2.02%
NRIX - MIRM
43%
Loosely correlated
-5.37%
DNLI - MIRM
41%
Loosely correlated
-0.34%
TARS - MIRM
40%
Loosely correlated
-1.10%
OCUL - MIRM
40%
Loosely correlated
+2.41%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with MIRM. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then MIRM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
+2.02%
MIRM - XERS
51%
Loosely correlated
-0.76%
AKBA - XERS
39%
Loosely correlated
+2.21%
KROS - XERS
38%
Loosely correlated
+3.37%
AXON - XERS
37%
Loosely correlated
-0.47%
PLRX - XERS
37%
Loosely correlated
+7.78%
More